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Background Case reports have suggested that cardiomyopathy may be a complica-
tion of recessive dystrophic epidermolysis bullosa (RDEB).
Objective To determine the risk of congestive heart failure (CHF) or cardiomyo-
pathy in each major EB subtype.
Methods These data represent systematic case ﬁndings and data collection per-
formed throughout the continental United States from 1986 through 2002, by
the National Epidermolysis Bullosa Registry. Study design is cross-sectional
(n = 3280) with a nested randomly sampled longitudinal subcohort (n = 450).
Frequencies of CHF and cardiomyopathy were determined by patient self-report-
ing, medical histories and review of medical records. In those who died, death
certiﬁcates were reviewed and histories obtained from surviving family. Cumula-
tive risks were stratiﬁed by cause and EB subtype.
Results Cardiomyopathy was reported as early as within the ﬁrst year of life. In
patients having no other known risk factors for CHF or cardiomyopathy, the
highest risk of cardiomyopathy was seen among patients with Hallopeau–
Siemens RDEB (RDEB-HS), with a cumulative risk of 4Æ51% on or after age
20 years. The cumulative risk of cardiomyopathy was only 1Æ14% and 0Æ40% in
non-Herlitz junctional EB (JEB) and non-Hallopeau–Siemens RDEB, respectively,
and was not observed in any other EB subtype. When patients with coexistent
chronic renal failure were included, the cumulative risk for RDEB-HS rose to
18Æ86% by age 35 years. About 30% of our patients affected with RDEB-HS died
of CHF or cardiomyopathy, even those with no other known risk factors.
Conclusions CHF and cardiomyopathy are uncommon complications in both major
RDEB subtypes and non-Herlitz JEB, and may be fatal.
Inherited epidermolysis bullosa (EB) encompasses four major
groups of skin diseases [epidermolysis bullosa simplex (EBS),
junctional epidermolysis bullosa (JEB), dominant dystrophic
epidermolysis bullosa (DDEB) and recessive dystrophic epi-
dermolysis bullosa (RDEB)], each characterized by marked
mechanical fragility of epithelial tissues and the formation of
blisters, erosions and poorly healing ulcers on the skin.
1–4
Approximately 25 clinically distinctive phenotypes
5 and hun-
dreds of genotypes have now been described, encompassing
mutations in at least 10 structural genes.
4,6–8 More clinical
variations and novel mutations will undoubtedly be reported
in the future, given the remarkably protean nature of this
group of diseases.
In 1996 two children with RDEB with dilated cardiomyopa-
thy were reported, one of whom had a low selenium level.
9
Echocardiographic examination of an additional 18 children
failed to reveal additional cases, raising a question about the
true frequency with which cardiomyopathy might occur in the
setting of RDEB. Since that time, a few other children with
RDEB have also been shown to have dilated cardiomyopathy.
10
The present study was undertaken to ascertain the frequency
of cardiomyopathy among the U.S. EB population, given the
availability of the robust numbers of clinically well-character-
ized patients enrolled in the National EB Registry. On the basis
of rigorous analysis of this registry’s database, we present data
on the cumulative risks for the development of congestive
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subtypes of this disease.
Patients and methods
Data were obtained from 3280 consecutively enrolled patients
with EB who were seen on behalf of the National EB Registry
from September 1986 to April 2002, when federal funding
for this National Institutes of Health (NIH)-supported project
formally ended. During these 16 years, work was carried out
by a number of co-investigators at several institutions (see
below for list of collaborating institutions). The authorship of
the present publication represents the research team at the
project’s Data Coordinating Center who took ultimate respon-
sibility for data validation and the performance and interpreta-
tion of all biostatistical analyses, in addition to playing a
pivotal role in data collection from the majority of the pro-
ject’s patients, their families and referring physicians.
Details of our data instrument and the methodologies used
in case ﬁnding have been reported previously.
11–13 Of note,
the questionnaire included ‘congestive heart failure⁄cardiomyo-
pathy’ as a response.
During the last 5 years of funding, all the work was con-
ﬁned to the University of North Carolina at Chapel Hill and
Stanford University, and was conducted under the auspices
and approval of the NIH-supported General Clinical Research
Centers and the Institutional Review Boards at each of these
two universities.
Whenever possible, each person enrolled was seen and
physically examined at least once by one of the project’s prin-
cipal investigators. The diagnosis of EB was conﬁrmed in every
case by immunoﬂuorescence antigenic mapping, EB-speciﬁc
monoclonal antibody studies and transmission electron
microscopy.
5 Each patient was further subclassiﬁed to EB sub-
type using a widely used classiﬁcation scheme that was
reported in 1991
14 and updated in 2000 by an international
panel of EB experts.
5
In order to allow more rigorous analyses, we separated our
patient population into several mutually exclusive EB subtypes,
following the detailed criteria of the most recent classiﬁcation
scheme:
5 EBS, Weber–Cockayne (EBS-WC); EBS herpetiformis,
Dowling–Meara (EBS-DM); EBS, Koebner (EBS-K); EBS, all
others (EBS-O); JEB, Herlitz (JEB-H); JEB, non-Herlitz sub-
types (JEB-O); DDEB; generalized RDEB, Hallopeau–Siemens
(RDEB-HS); and generalized RDEB, non-Hallopeau–Siemens
(RDEB-nHS). Only 17 patients with RDEB inversa were
enrolled in the project, and as none of them experienced CHF
or cardiomyopathy, they were not included within the present
set of analyses. Sufﬁcient data existed on 2750 enrollees
(83Æ8%) to permit subclassiﬁcation into these major EB sub-
types. This served as the ﬁnal subpopulation from which car-
diac data were extracted.
Approximately 450 well-classiﬁed subjects were further ran-
domly selected for longitudinal follow-up on an every 2-year
basis during the last 10 years of this project.
11 This nested
subpopulation was chosen so as to maximally sample those EB
subtypes most at risk for signiﬁcant extracutaneous complica-
tions, the latter based on previous publications.
All patients who reported having had CHF or cardiomyopa-
thy were interviewed for further details of their signs and
symptoms, as well as for the source of each diagnosis. Fami-
lies of deceased patients were identically interviewed. The
diagnosis of CHF was made by the presence of classic clinical
ﬁndings and cardiomegaly on chest X-ray. For purposes of
our analyses, the diagnosis of cardiomyopathy was reserved
for those patients being given that diagnosis by their phys-
icians. In those who had died, death certiﬁcates or autopsy
reports served as another conﬁrmation of the diagnosis. None
of our patients underwent cardiac biopsies, however, to per-
mit deﬁnitive tissue conﬁrmation of cardiomyopathy.
Among the entire National EB Registry study population, 21
patients were reported to have had CHF or cardiomyopathy.
Of these, six were eliminated from initial analysis following
careful review of their medical records or interviews of the
patients or their families. Reasons included lack of evidence of
any cardiac disease including CHF (n = 1); presence of con-
genital heart disease (n = 1) or rheumatic heart disease
(n = 1); onset at age 65 years of CHF as a consequence of
atherosclerotic heart disease (n = 1); or lack of data on the
time of onset of either CHF or cardiomyopathy (n = 2).
Three groups of patients were then separated for analysis:
group 1 (n = 15), all patients reported to have CHF or CM,
including ﬁve patients who had chronic renal failure [due to
glomerulonephritis (n = 1), renal amyloidosis (n = 1),
unknown aetiology (n = 3)]; group 2 (n = 10), excluding
those having concurrent chronic renal failure; group 3
(n = 7), comprising only those patients who speciﬁcally car-
ried the diagnosis of cardiomyopathy from a physician and
lacked any other discernible potential confounding causes of
CHF (including renal failure and other types of heart disease,
acquired or congenital). In each of these patients, signs and
symptoms of CHF, including cardiomegaly, were also present.
This third group was believed to represent the most accurate
estimate of possible cardiomyopathy among our entire EB
study population.
Data were entered into specially designed templates origi-
nally based on Clinfo and later on EpiInfo software (Centers
for Disease Control, Atlanta, GA, U.S.A.). SAS datasets (SAS
Institute, Cary, NC, U.S.A.) were subsequently generated to
facilitate the performance of lifetable analyses. All biostatistical
analyses were conducted under the direct supervision of the
project’s designated biostatistician (C.S.). Computer-generated
graphs were created using Excel.
Results
Frequencies of congestive heart failure
or cardiomyopathy
CHF and cardiomyopathy were reported in only three EB sub-
types – JEB-O, RDEB-HS and RDEB-nHS – among all of the
participants in the National EB Registry. Table 1 summarizes
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affected was RDEB-HS, with about 7% reporting one of these
complications. When cases were conﬁned to those patients in
whom the diagnosis of cardiomyopathy was speciﬁed in writ-
ing by a physician, the frequency dropped to about 3Æ6%.
Only about 1% of patients with JEB-O or RDEB-nHS were
noted to have had either CHF or cardiomyopathy, with fre-
quencies dropping to about 0Æ5% and 0Æ4%, respectively,
when only cardiomyopathy was considered.
Cumulative and conditional risks of congestive heart
failure or cardiomyopathy
Group 1 included all patients who were reported to have CHF
or cardiomyopathy, and on whom age of onset was known,
regardless of whether concurrent chronic renal failure was
present. The highest risk was noted in those with RDEB-HS,
with a cumulative risk of 0Æ72% by age 2, rising to 1Æ45%,
2Æ28%, 4Æ28%, 6Æ73%, 8Æ72%, and 18Æ86% by ages 3, 9, 15,
20, 25 and 35 (through age 65), respectively. The highest
conditional risk, 11Æ11%, occurred between ages 30 and 35.
Among those with RDEB-nHS, the cumulative risks were only
0Æ4%, 1Æ35%, and 2Æ75% at ages 1, 20 and 30 (through age
80), and in JEB-O, they were 1Æ14%, 1Æ14% and 4Æ94% by
ages 3, 35 and 40 (through age 70), respectively.
Figure 1 depicts the cumulative risk of CHF or cardiomyo-
pathy within group 2 of our patient population, which
excluded any patient who had a history of concurrent chronic
renal failure. This complication was ﬁrst reported by ages 3, 2
and 1 year of life in patients with JEB-O, RDEB-HS and RDEB-
nHS, respectively. Among patients with JEB-O, the cumulative
risk was 1Æ14% by age 3, rising to 4Æ94% on or after age
40 years, with the highest conditional risk, 3Æ85%, occurring
between ages 35 and 40. In patients with RDEB-HS, the
cumulative risks were 0Æ72%, 1Æ45%, 2Æ28% and 5Æ52% by
ages 2, 3, 9 and 20 years. The highest conditional risk,
1Æ29%, occurred between ages 15 and 20. In our RDEB-nHS
subpopulation, the cumulative risks were 0Æ40% and 1Æ81% by
ages 1 and 30, respectively.
Figure 2 depicts the cumulative risk of cardiomyopathy
among those patients lacking other discernible causes of CHF
(group 3). Among patients with RDEB-HS, cumulative risks
were 0Æ72%, 1Æ45%, 2Æ28%, 3Æ26%, and 4Æ51% by ages 2, 3,
9, 13 and 20 years, respectively, with the highest conditional
risk, 1Æ29%, arising between ages 15 and 20 years. In contrast,
the maximum cumulative risks in JEB-O and RDEB-nHS were
1Æ14% and 0Æ40% by ages 3 and 1, respectively.
Risk of death from congestive heart failure
or cardiomyopathy
Among group 2, three out of 10 (30%) patients, all with
RDEB-HS, died as a result of CHF or cardiomyopathy at ages
Table 1 Frequencies of congestive heart failure (CHF) and










JEB-O 2 ⁄194 (1Æ04) 2 ⁄194 (1Æ04) 1 ⁄194 (0Æ52)
RDEB-HS 10 ⁄140 (7Æ14) 6 ⁄140 (4Æ29) 5 ⁄140 (3Æ57)
RDEB-nHS 3 ⁄267 (1Æ12) 2 ⁄267 (0Æ75) 1 ⁄267 (0Æ37)
EB, epidermal bullosa; CRF, chronic renal failure; JEB-O, junc-
tional EB, non-Herlitz subtypes; RDEB-HS, recessive dystrophic
EB, Hallopeau–Siemens; RDEB-nHS, RDEB, non-Hallopeau–
Siemens.
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Fig 1. Age-dependent cumulative risk of congestive heart failure
(CHF) or cardiomyopathy in inherited epidermolysis bullosa (EB)
expressed as percentage and stratiﬁed by EB subtype. JEB-O, junctional
EB, non-Herlitz subtypes; RDEB-HS, recessive dystrophic EB,
Hallopeau–Siemens; RDEB-nHS, RDEB, non-Hallopeau–Siemens.
Fig 2. Age-dependent cumulative risk of cardiomyopathy in inherited
epidermolysis bullosa (EB) expressed as percentage and stratiﬁed by
EB subtype. JEB-O, junctional EB, non-Herlitz subtypes; RDEB-HS,
recessive dystrophic EB, Hallopeau–Siemens; RDEB-nHS, RDEB,
non-Hallopeau–Siemens.
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3, two deaths (out of seven, 28Æ6%) were directly attributed
to cardiomyopathy. An additional patient with JEB-O who was
also included within groups 2 and 3 died at age 3 of respira-
tory insufﬁciency following anaesthesia; dilated cardiomyo-
pathy was noted at autopsy but was not listed as a cause of
death. Two other patients with RDEB-HS included within
group 1, who had concurrent chronic renal failure, reportedly
died of CHF or cardiomegaly at ages 21 and 31 years. The
older of these two also had numerous transfusions, which
may have contributed to iron overload, whereas the younger
patient with chronic renal failure had her renal disease for
5 years prior to the onset of CHF, and then died 3 months
later, reportedly as a result of the latter complication.
Discussion
The term cardiomyopathy, ﬁrst used in 1957, now encom-
passes three main subtypes – dilated, hypertrophic (idiopathic
hypertrophic subaortic stenosis) and restrictive cardiomyo-
pathies.
15 A characteristic feature of dilated cardiomyopathy is
CHF. There are many suggested causes of dilated cardiomyo-
pathy, including micronutrient deﬁciencies (carnitine,
16–18
selenium,




infections (presenting as myocarditis).
24–26 Of clinical perti-
nence to EB, the causal association of cardiomyopathy with
selenium deﬁciency has recently been challenged.
21,27
The ﬁrst case of dilated cardiomyopathy in RDEB was
reported in 1989 in a 17-year-old patient who had undergone
repeated transfusions since age 9 years.
28 At that time it was
believed that this complication was caused by iron overload
and secondary haemosiderosis. In 1996, Melville et al.
9
reported the presence of fatal dilated cardiomyopathy in two
unrelated children with RDEB. One child was found to have
low selenium levels, suggesting that this micronutrient deﬁ-
ciency might be the possible cause. However, low selenium
levels were also found in 14 of 25 other children with RDEB
lacking evidence of cardiac disease, raising a question as to
the clinical relevance of this ﬁnding in only one of the two
children with cardiomyopathy. In a follow-up study with
7 years of observation, dilated cardiomyopathy was detected
in six out of 61 (9Æ8%) children with RDEB who were evalu-
ated within the same institution.
10 The mean age of conﬁrm-
ation of the diagnosis by echocardiography was 8Æ7 years
(range 5Æ8–12Æ5). Three of these six children died of their car-
diac disease within 0Æ2t o0 Æ4 years. When data on each of
these 61 patients were reviewed, statistically signiﬁcant reduc-
tions in blood levels of free and total carnitine, but not sele-
nium, were noted prior to nutritional supplementation, and
none of these children was found to have any coexistent viral
infection that might have played a causative role. These latter
ﬁndings suggest the possibility that carnitine supplementation
in recessive dystrophic EB children might be preventative
against the development of dilated cardiomyopathy. In support
of the latter, L-carnitine therapy has reversed cardiomyopathy
in some patients having other underlying diseases associated
with carnitine deﬁciency.
16,29
Our ﬁndings are limited by the strength of the data col-
lected, given the epidemiological study design of the National
EB Registry. As noted elsewhere, these data may have been
inﬂuenced by patient self-reporting, allowing for the possible
introduction of reporting bias. Similarly, lack of cardiac mus-
cle biopsy specimens and details of echocardiograms prevent
deﬁnitive determination of the presence of cardiomyopathy, as
opposed to some other cause of CHF. These data are therefore
theoretically at risk of being inﬂuenced by misclassiﬁcation
bias, with under- or over-reporting of the frequency with
which both conditions occur in patients with EB. However,
every effort was made to conﬁrm these diagnoses via system-
atic detailed interviews of patients and their immediate family
(if deceased), and the review of their medical records, when-
ever available. As such, we are conﬁdent that all of these
affected patients experienced at least CHF. Furthermore, since
we excluded from our analyses any other known causes of
CHF in children (i.e. congenital heart defects producing myo-
cardial overload, or cardiac dysfunction resulting from their
surgical repair or palliation),
30 it is probable that most or all
of our patients diagnosed with CHF did indeed have underly-
ing dilated cardiomyopathy.
As noted previously, we grouped our patients into three
increasingly restrictive strata, so as to ascertain the maximum
(group 1) and minimum (group 3) cumulative risks for the
development of cardiomyopathy among our large, well-
characterized EB population. Group 1 represents the risk of
CHF after all other identiﬁable confounders other than chronic
renal failure were excluded. This would therefore capture all
patients with cardiomyopathy, as well as those having other
explanations for the presence of CHF, most notably chronic
renal failure. Groups 2 and 3 were speciﬁcally considered sep-
arately, as a particular concern has been raised in the literature
that cardiomyopathy might, in the setting of RDEB-HS, be
caused by micronutrient deﬁciency, either carnitine or sele-
nium. Among our patients in group 1, the cumulative risk
rose as high as 18Æ86% for patients with RDEB-HS, 2Æ75% in
RDEB-nHS and 4Æ94% in JEB-O. This makes the point that
CHF is a clinically signiﬁcant concern among patients with EB,
most notably those with RDEB-HS, and, when compared with
groups 2 and 3, that the chronic renal failure plays an impor-
tant role in the development of CHF in these speciﬁc EB sub-
types. While it is known that chronic renal failure may be a
complication of RDEB-HS, typically the result of chronic glo-
merulonephritis or renal amyloidosis, and that chronic renal
failure may be associated with CHF, it is not usually included
among the causes of cardiomyopathy. When patients with
chronic renal failure were excluded, as were those lacking a
deﬁnitive diagnosis of cardiomyopathy, the cumulative risk of
cardiomyopathy among EB patients was much lower, albeit
still clinically signiﬁcant.
Based on our data, in the absence of chronic renal failure,
CHF and cardiomyopathy are uncommon occurrences among
patients with EB, with the highest cumulative risks (4Æ51%)
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ved in patients with RDEB-HS. Lower cumulative risks also
occurred in two other generalized EB subtypes, RDEB-nHS and
JEB-O. These risks are much higher than those of the general
population, where an annual incidence of cardiomyopathy of
1Æ1–1Æ2 per 100 000 children has been estimated for Austra-
lia
31 and the U.S.A.
32 It is also noteworthy that about 30% of
our patients with RDEB-HS who had CHF or cardiomyopathy
died as a result of these cardiac complications. Of clinical sig-
niﬁcance, none of our patients had evidence of ischaemic
heart disease or any congenital cardiac anomaly that might
alternatively explain the presence of CHF. Unfortunately,
selenium and carnitine levels were not obtained for any
of our affected patients, as much of our data collection
preceded any suggestion within the literature that cardiac
complications might arise in the setting of EB, or that sele-
nium or carnitine deﬁciencies might play a pathological role
in this disease.
It is quite likely that chronic anaemia, a well-recognized
cause of dilated cardiomyopathy, plays a clinically relevant
role in the development of CHF and cardiomyopathy in severe
generalized EB, particularly RDEB-HS. Consistent with that, all
of our patients with RDEB-HS suffered from severe multifacto-
rial anaemia, although lack of data on haemoglobin levels at
the time of onset or diagnosis of these cardiac ﬁndings pre-
vents any quantitative comparison between those patients with
and those without CHF or cardiomyopathy. Similarly,
although it is known that patients with RDEB-nHS and JEB-O
may also experience some degree of anaemia, insufﬁcient data
among our cohort prevent testing for any possible quantitative
correlation with that risk factor in either of these two EB
subtypes.
On the basis of our collective ﬁndings, surveillance for evi-
dence of CHF and cardiomyopathy seems prudent in all
infants and children with RDEB-HS, RDEB-nHS and JEB-O.
Serum levels of carnitine and selenium should be monitored
for possible deﬁciencies which could be reversed by aggressive
nutritional supplementation. Similarly, haematological testing
should be part of the routine management of patients with
severe generalized EB, most notably RDEB-HS, and interven-
tions should be undertaken to try to increase, at least partially,
haemoglobin levels in those with severe anaemia. Based on
our data, the presence of renal disease should also be sought,
since it is clear that chronic renal failure also plays a role
in the risk of CHF arising among patients with severe general-
ized EB.
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